Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Eli Lilly & Co (LLY) yesterday and set a price target of $143. The company’s shares closed yesterday at $124.31, close to its 52-week high of $130.75.
Chen observed:
“. We have updated our LLY model to exclude Elanco as of 1/1/19. This results in an increase in our 2019 EPS estimate to $5.63 from $5.55. We view the separation of Elanco (Not Covered) as positive for both LLY and Elanco, since the companies can now focus and be recognized for their core capabilities. Therefore, we are reiterating our OW rating and $143 PT for LLY shares post the offering.”
According to TipRanks.com, Chen is a 5-star analyst with an average return of 14.0% and a 40.0% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Amneal Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Eli Lilly & Co with a $128.90 average price target, a 3.7% upside from current levels. In a report issued on March 1, BMO Capital also maintained a Buy rating on the stock with a $134 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $130.75 and a one-year low of $74.51. Currently, Eli Lilly & Co has an average volume of 15.31M.
Based on the recent corporate insider activity of 137 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
